지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2024.3
- 수록면
- 283 - 293 (11page)
- DOI
- 10.5009/gnl230128
이용수
초록· 키워드
오류제보하기
Background/Aims: Noninvasive methods have become increasingly critical in the diagnosis of fibrosis in chronic liver diseases. Herein, we compared the diagnostic performance of serum Mac2 binding protein glycosylation isomer (M2BPGi) and other serological panels for fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) and proposed an improved two-step diagnostic algorithm for advanced fibrosis.
Methods: We enrolled 231 patients diagnosed with NAFLD who underwent a liver biopsy. We subsequently evaluated the diagnostic performance of serological panels, including serum M2BPGi, a fibrosis index based on four factors (FIB-4), aspartate aminotransferase-to-platelet ratio index (APRI), and NAFLD fibrosis score (NFS), in predicting the stage of liver fibrosis. We then constructed a two-step algorithm to better differentiate advanced fibrosis.
Results: The areas under the receiver operating characteristic curves of serum M2BPGi, FIB-4, APRI, and NFS for advanced fibrosis (≥F3) were 0.823, 0.858, 0.779, and 0.827, respectively.
To reduce the performance of unnecessary liver biopsy, we propose a two-step algorithm using FIB-4 as an initial diagnostic tool and serum M2BPGi (≥0.6) as an additional diagnostic method for patients classified as intermediate (23%). Using the proposed algorithm, the sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were 0.812, 0.814, 0.814, 0.600, and 0.927, respectively.
Conclusions: Serum M2BPGi is a simple and effective test for advanced fibrosis in patients with NAFLD. Application of the two-step algorithm based on FIB-4 and M2BPGi proposed here can improve diagnostic performance and reduce unnecessary tests, making diagnosis easily accessible, especially in primary medical centers.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Diagnostic Efficacy of Serum Mac-2 Binding Protein Glycosylation Isomer and Other Markers for Liver Fibrosis in Non-Alcoholic Fatty Liver Diseases
Annals of Laboratory Medicine
2021 .01
-
Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases
Annals of Laboratory Medicine
2021 .01
-
Usefulness of Enhanced Liver Fibrosis, Glycosylation Isomer of Mac-2 Binding Protein, Galectin-3, and Soluble Suppression of Tumorigenicity 2 for Assessing Liver Fibrosis in Chronic Liver Diseases
Annals of Laboratory Medicine
2018 .01
-
만성 B형간염에 의한 간세포암 환자에서 간경변 진단을 위한 M2BPGi, Fibroscan 및 기타 간섬유화 표지자 비교
Laboratory Medicine Online
2020 .01
-
Accuracy of Noninvasive Scoring Systems in Assessing Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Gut and Liver
2022 .11
-
Comparison of Non-Invasive Clinical Algorithms for Liver Fibrosis in Patients With Chronic Hepatitis B to Reduce the Need for Liver Biopsy: Application of Enhanced Liver Fibrosis and Mac-2 Binding Protein Glycosylation Isomer
Annals of Laboratory Medicine
2022 .03
-
Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Diabetes and Metabolism Journal
2022 .07
-
Beyond Liver Disease: Non-Alcoholic Fatty Liver Disease and Advanced Liver Fibrosis in Kidney Disease
Diabetes and Metabolism Journal
2022 .07
-
Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective
Clinical and Molecular Hepatology
2021 .01
-
Mac-2 Binding Protein Glycosylation Isomer: Emerging Non-Invasive Serum Marker for Liver Fibrosis
Annals of Laboratory Medicine
2018 .01
-
Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future
Clinical and Molecular Hepatology
2023 .02
-
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
Clinical and Molecular Hepatology
2023 .02
-
Identification of high-risk subjects in nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2023 .02
-
Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease
Clinical and Molecular Hepatology
2023 .04
-
Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease
Endocrinology and Metabolism
2020 .01
-
Association of Myosteatosis with Nonalcoholic Fatty Liver Disease, Severity, and Liver Fibrosis Using Visual Muscular Quality Map in Computed Tomography
Diabetes and Metabolism Journal
2023 .01
-
Serologic Biomarkers for Hepatic Fibrosis in Obese Children with Nonalcoholic Steatohepatitis
Pediatric Gastroenterology, Hepatology & Nutrition
2024 .07
-
Simple Noninvasive Scores Are Clinically Useful to Exclude, Not Predict, Advanced Fibrosis: A Study in Turkish Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease
Gut and Liver
2020 .01
-
Noninvasive Serum Fibrosis Markers are Associated with Coronary Artery Calcification in Patients with Nonalcoholic Fatty Liver Disease
Gut and Liver
2019 .01
-
Severe Phenotype of Non-alcoholic Fatty Liver Disease in Pediatric Patients with Subclinical Hypothyroidism: a Retrospective Multicenter Study from Korea
Journal of Korean Medical Science
2021 .01
최근 본 자료
댓글(0)
0